# | Title | Journal | Year | Citations |
---|
1 | CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy | Nature | 2019 | 1,528 |
2 | Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2019 | 943 |
3 | Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2020 | 848 |
4 | Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2019 | 700 |
5 | Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2019 | 672 |
6 | Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11 | Cancer Discovery | 2019 | 566 |
7 | Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2022 | 562 |
8 | Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination | Nature Medicine | 2021 | 451 |
9 | NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018 | Journal of the National Comprehensive Cancer Network: JNCCN | 2018 | 394 |
10 | Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2019 | 393 |
11 | Distress Management, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2019 | 385 |
12 | Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2020 | 383 |
13 | Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial | Lancet Oncology, The | 2020 | 330 |
14 | Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group | Journal of the National Cancer Institute | 2021 | 319 |
15 | Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2019 | 314 |
16 | NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020 | Journal of the National Comprehensive Cancer Network: JNCCN | 2020 | 314 |
17 | Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2019 | 298 |
18 | NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020 | Journal of the National Comprehensive Cancer Network: JNCCN | 2020 | 284 |
19 | Guidelines Insights: Pancreatic Adenocarcinoma, Version 1.2019 | Journal of the National Comprehensive Cancer Network: JNCCN | 2019 | 281 |
20 | Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer | Cell Metabolism | 2019 | 280 |
21 | Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium | Annals of Oncology | 2021 | 240 |
22 | Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2018 | 202 |
23 | NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019 | Journal of the National Comprehensive Cancer Network: JNCCN | 2019 | 200 |
24 | Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial | Lancet Haematology,the | 2019 | 194 |
25 | Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study | Lancet Oncology, The | 2020 | 194 |
26 | NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018 | Journal of the National Comprehensive Cancer Network: JNCCN | 2018 | 192 |
27 | NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2019 | Journal of the National Comprehensive Cancer Network: JNCCN | 2019 | 191 |
28 | NCCN Guidelines Insights: Kidney Cancer, Version 2.2020 | Journal of the National Comprehensive Cancer Network: JNCCN | 2019 | 185 |
29 | Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma | Blood | 2019 | 184 |
30 | NCCN Guidelines Insights: Bladder Cancer, Version 5.2018 | Journal of the National Comprehensive Cancer Network: JNCCN | 2018 | 171 |
31 | NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022 | Journal of the National Comprehensive Cancer Network: JNCCN | 2022 | 169 |
32 | NCCN Guidelines Insights: Kidney Cancer, Version 1.2021 | Journal of the National Comprehensive Cancer Network: JNCCN | 2020 | 163 |
33 | Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy | Cancer Research | 2019 | 154 |
34 | Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19 | JAMA Oncology | 2021 | 149 |
35 | Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2020 | 147 |
36 | Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial | Lancet Oncology, The | 2022 | 147 |
37 | Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update | Journal of Clinical Oncology | 2022 | 139 |
38 | Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2022 | 124 |
39 | NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019 | Journal of the National Comprehensive Cancer Network: JNCCN | 2019 | 116 |
40 | Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine | Clinical Cancer Research | 2018 | 114 |
41 | Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2018 | 113 |
42 | NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021 | Journal of the National Comprehensive Cancer Network: JNCCN | 2021 | 113 |
43 | NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020 | Journal of the National Comprehensive Cancer Network: JNCCN | 2019 | 113 |
44 | Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy | Journal of Clinical Investigation | 2020 | 112 |
45 | O-GlcNAc Transferase Suppresses Inflammation and Necroptosis by Targeting Receptor-Interacting Serine/Threonine-Protein Kinase 3 | Immunity | 2019 | 111 |
46 | HPV16 drives cancer immune escape via NLRX1-mediated degradation of STING | Journal of Clinical Investigation | 2020 | 104 |
47 | HER2 and Breast Cancer — A Phenomenal Success Story | New England Journal of Medicine | 2019 | 102 |
48 | Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2020 | 102 |
49 | NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021 | Journal of the National Comprehensive Cancer Network: JNCCN | 2021 | 98 |
50 | Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study | Journal of Clinical Oncology | 2021 | 97 |